Blood tests offer new hope in detecting Alzheimer's

The advent of blood testing in diagnosing Alzheimer’s disease has led to a paradigm shift in the medical world.

This innovation opens up new possibilities for timely detection and offers hope for the early application of treatments – a critical factor considering the emergence of new Alzheimer’s therapies that could change the disease’s trajectory.

Although the potential of blood tests is undoubtedly promising, it raises an essential question regarding their reliability.

Which of these tests accurately detect Alzheimer’s? The answer was shrouded in mystery as there had not been a head-to-head comparison of the tests.

Battle of the Alzheimer’s blood tests

Grappling with this challenge, a team of experts led by Dr. Suzanne Schindler at Washington University School of Medicine in St. Louis took on the vital task of comparing the accuracy of commercially available blood tests.

The research efforts were centered around six blood tests, four of which are currently clinically available.

The goal? To determine which tests were best at identifying the hallmark of Alzheimer’s disease – the presence of characteristic amyloid plaques in the brain.

The results, unveiled at the Alzheimer’s Association International Conference, revealed that some of the tests have the potential to replace conventional and invasive procedures such as spinal taps and brain scans in many patients.

Deciphering the diagnostic dilemma

“Some of the blood tests are accurate, and some are not, and doctors don’t know which tests to use,” noted Dr. Schindler.

However, this head-to-head comparison has now provided medical practitioners with more trustworthy information, equipping them to provide accurate diagnoses to their patients.

The significance of an early and accurate diagnosis of Alzheimer’s disease cannot be understated, especially with the advent of new treatment options.

The Food and Drug Administration (FDA) has endorsed two new drugs that slow the disease’s progression. However, these drugs are only effective for individuals with very mild to mild symptoms.

To prescribe these treatments, doctors must be certain of the presence of amyloid buildup in the patient’s brain, which is a condition that these blood tests can identify.

The quest for the ideal biomarker

The six blood tests under study were developed by diverse groups. The teams behind these tests are from ALZpath, C2N Diagnostics, Fujirebio Diagnostics, Janssen, Quanterix, and Roche Diagnostics.

Interestingly, C2N Diagnostics is a startup supported by Washington University. Each of these tests measured the blood levels of one or more biomarkers linked to Alzheimer’s disease.

Across these tests were five distinct biomarkers assessed using different techniques. However, one biomarker, phosphorylated tau 217 (p-tau217), surpassed the others in accurately identifying signs of Alzheimer’s disease.

“Some people thought that we might need to measure multiple biomarkers to capture the different features of Alzheimer’s disease. That’s not what we found. P-tau217 alone can do it all,” said Dr. Kellen Petersen, an instructor in neurology at the School of Medicine.

The top performing tests

Of the tests studied, those incorporating measures of p-tau217 displayed remarkable accuracy.

The highest-ranking tests were C2N Diagnostics’ PrecivityAD2 and Fujirebio’s Lumipulse. In their analysis, the scientists concluded that for a blood test to be used without additional testing, it should be as accurate as FDA-approved cerebrospinal fluid tests, which are approximately 90% sensitive and specific.

The significant findings of this elaborate comparison study act as guiding light in the pursuit of the ideal diagnostic tool for Alzheimer’s disease – suggesting the game-changing potential of blood tests in detecting and managing this challenging illness.

The future of Alzheimer’s diagnosis and treatment

As we stand on the brink of this new era in Alzheimer’s diagnosis, the implications extend far beyond mere testing.

Advancements in blood testing could pave the way for more personalized treatment plans tailored to individual patients’ needs, enhancing the efficacy of emerging therapies.

Additionally, as the accuracy of these blood tests improves, they may facilitate wider access to early diagnosis, particularly in underserved populations who may not have the opportunity for traditional diagnostic methods.

Moreover, ongoing research into additional biomarkers holds the promise of unveiling more comprehensive insights into Alzheimer’s disease, potentially leading to breakthrough treatments.

Collaborations between academic institutions, biotech companies, and healthcare providers will be crucial in driving this innovation forward, ensuring that the benefits of these advancements reach those who need them most.

The future looks promising, and it is our collective responsibility to harness these developments to improve Alzheimer’s care and research.

—–

Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates. 

Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.

—–